Study shows Artelon scaffold improves cartilage repair outcome

“The results offer good conditions and proof of concept for Artimplant to develop additional products for the treatment of cartilage injuries.”

Artimplant AB (STO:ARTIB)

A laboratory study (in vitro) and an animal study, which are currently being presented at the 9th World Congress of the International Cartilage Repair Society, demonstrate that Artelon® functions as a scaffold for cells in conjunction with cartilage repair.

Both locally recruited cells obtained through bleeding as well as in vitro cultured human chondrocytes, which are currently in clinical use, have been studied. The results show that the newly formed tissue is improved with the use of Artelon®.

Professor Lars Peterson, Sahlgrenska University Hospital, has led the animal study:

"There is a considerable clinical need to improve the outcome of cartilage repair. The studies show the potential that exists in the Artelon® material as a scaffold and that it contributes to tissue healing."

Dr. Sebastian Concaro, orthopedic surgeon and also involved in the animal study:

"The results are very promising and show that the material is well tolerated in the joint and provides good cartilage repair."

Dr. Katrin Gisselfält, VP Research & Development at Artimplant:

"The results offer good conditions and proof of concept for Artimplant to develop additional products for the treatment of cartilage injuries."

Source:

: Artimplant

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New toolkit aims to help U.S. hospitals spot deadly viral hemorrhagic fevers faster and safer